TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18842788

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (daily tablet containing 15 micronutrients at just above the recommended nutrient intake)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 500
Study: 16053527

Group type: EXPERIMENTAL
Intervention: self‐help manual and enhanced stage‐based counselling
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: self‐help manual, enhanced stage‐based counselling and use of an interactive computer program
Number of subjects: 918

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 918
Study: 12209296

Group type: EXPERIMENTAL
Intervention: Tacker device (spiral titanium tacks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Running 2-0 polypropylene suture
Number of subjects: 34
Study: 10487375

Group type: COMPARATOR
Intervention: Diet-only group (D; N = 8)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Diet group with aerobic exercise (DE; N = 11)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Diet group with aerobic and strength training (DES; N = 10)
Number of subjects: 35
Study: 8923125

Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tricyclic Antidepressants (TCAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0
Study: 1679243

Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg (single oral dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6415364

Group type: EXPERIMENTAL
Intervention: Hormone treatment with 4 mg oestradiol
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Hormone treatment with 2 mg oestradiol
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Hormone treatment with 1 mg oestradiol
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Withdrawal of hormone treatment
Number of subjects: 131
Study: 30320964

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg every 28 days plus standard therapy
Number of subjects: 268
Study: 29624575

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26294070

Group type: EXPERIMENTAL
Intervention: Low-dose isoflavone aglycone (25 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 25248831

Group type: EXPERIMENTAL
Intervention: Interactive education group (Group I)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pamphlet education group (Group II)
Number of subjects: 96
Study: 22974080

Group type: EXPERIMENTAL
Intervention: Mobile Diabetes Education Teams (MDETs) intervention
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (clusters randomized to receive intervention later)
Number of subjects: 1200
Study: 20067326

Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated plaster
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated plaster (realistic usage)
Number of subjects: 0
Study: 17400850

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally and misoprostol 800 mcg vaginally administered simultaneously
Number of subjects: 1128

Group type: COMPARATOR
Intervention: Mifepristone 200 mg orally and misoprostol 800 mcg vaginally administered 24 hours apart
Number of subjects: 1128
Study: 16142748

Group type: COMPARATOR
Intervention: HuMax-IL15
Number of subjects: 30
Study: 12729424

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg intravenously every 12 hours for 2 days followed by 200 mg intravenously every 24 hours or a 200‐mg oral solution every 12 hours)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Fluconazole (400 mg intravenously or orally every 24 hours)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 140

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 140
Study: 10717733

Group type: EXPERIMENTAL
Intervention: Insecticide-treated materials (ITMs) with lambdacyhalothrin
Number of subjects: 19

Group type: COMPARATOR
Intervention: General health education (Control)
Number of subjects: 19
Study: 8952557

Group type: COMPARATOR
Intervention: Tetracycline (20 mg/kg [maximum of 2 g] in 50 mL of normal saline)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bleomycin (1 U/kg [maximum of 60 U] in 50 mL of normal saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of tetracycline (20 mg/kg [maximum of 2 g] in 40 mL of normal saline) and bleomycin (1 U/kg [maximum of 60 U] in 30 mL of normal saline)
Number of subjects: 60
Study: 1798305

Group type: EXPERIMENTAL
Intervention: Active recovery (cycling at 30% VO2max)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Passive recovery (sitting quietly)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control test (no recovery)
Number of subjects: 5
Study: 7381634

Group type: EXPERIMENTAL
Intervention: Cloxacillin administered intravenously for ten days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Carbenicillin plus gentamicin administered intravenously for ten days
Number of subjects: 22
Study: 30381936

Group type: EXPERIMENTAL
Intervention: Peer education intervention (intensive three-day training for peer educators)
Number of subjects: 20
Study: 26984117

Group type: EXPERIMENTAL
Intervention: Community-led and community-implemented CBPR strategy for recruiting
Number of subjects: 160
Study: 25320597

Group type: COMPARATOR
Intervention: Dexamethasone 8mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone 8mg and ondansetron 4mg
Number of subjects: 108
Study: 22464089

Group type: EXPERIMENTAL
Intervention: True noninvasive limb cover
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham noninvasive limb cover
Number of subjects: 57
Study: 20445999

Group type: EXPERIMENTAL
Intervention: Patients with deep surgical site infections (SSI) following spinal fusion
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 1

Group type: COMPARATOR
Intervention: Uninfected patients (control group)
Number of subjects: 1
Study: 18762508

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 101

Group type: COMPARATOR
Intervention: Oral sucrose solution (1 mL of 25% sucrose solution)
Number of subjects: 101
Study: 15785924

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% applied topically, twice a day for 4-48 hours before laser treatment and continued for 1 month.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (matched control group), applied topically, twice a day for 4-48 hours before laser treatment and continued for 1 month.
Number of subjects: 20
Study: 12498584

Group type: EXPERIMENTAL
Intervention: Intervention group (increased bedroom temperature by at least 3 degrees C)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no temperature increase)
Number of subjects: 28
Study: 10363725

Group type: EXPERIMENTAL
Intervention: HLA antigen B63 in patients with HPV types other than HPV 16 or 18
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: HLA antigen B55 in patients negative for all HPV types
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: HLA antigen DR15
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: HLA antigen DR3 in patients with HPV types other than HPV 16 or 18
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: HLA antigen DR11 among HPV 16 positive patients
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: HLA antigen DR13
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: HLA antigens DR15 and DQ4 in CIN patients
Number of subjects: 288
Study: 7738792

Group type: EXPERIMENTAL
Intervention: Enoximone bolus single dose (0.25‐2.0 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoximone continuous infusion (4‐h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoximone bolus multiple doses (four consecutive doses at 3‐h intervals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoximone (various administrations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of pharmacokinetic parameters in Japanese and Caucasian volunteers
Number of subjects: 0
Study: 2028004

Group type: EXPERIMENTAL
Intervention: Ionic contrast media
Number of subjects: 101

Group type: COMPARATOR
Intervention: Nonionic (low‐osmolality) contrast agents
Number of subjects: 101
Study: 6797454

Group type: EXPERIMENTAL
Intervention: MR 1268 2.5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: MR 1268 5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: MR 1268 10 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: MR 1268 20 mg
Number of subjects: 6
Study: 31014702

Group type: EXPERIMENTAL
Intervention: 3D HUD surgical platform
Number of subjects: 39

Group type: COMPARATOR
Intervention: SOM
Number of subjects: 39
Study: 28415943

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.5% bupivacaine (Group B, n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.5% levobupivacaine (Group L, n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline as a placebo (Group C, n = 30)
Number of subjects: 90
Study: 25903217

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol self-administration (up to a maximum BAC of 160 mg% in study 1 and 120 mg% in study 2)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-exposed age-matched control group (42 participants)
Number of subjects: 78
Study: 23574969

Group type: EXPERIMENTAL
Intervention: Etanercept (10 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study: 21329577

Group type: EXPERIMENTAL
Intervention: Anhedonia (lack of pleasure)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 82
Study: 19629797

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (CBT)
Number of subjects: 211
Study: 16687482

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Brace only
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of physiotherapy and brace
Number of subjects: 180
Study: 15293491

Group type: EXPERIMENTAL
Intervention: Multidisciplinary back school programme (Roessingh Back Rehabilitation Programme, RRP)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 163
Study: 11420761

Group type: EXPERIMENTAL
Intervention: wet/cold profile
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: wet/warm profile
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: dry/cold profile
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: dry/warm profile
Number of subjects: 440
Study: 9165176

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise added to medical antihypertensive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical antihypertensive therapy (indapamide +/- verapamil +/- enalapril)
Number of subjects: 0
Study: 8210016

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 48
Study: 2681547

Group type: EXPERIMENTAL
Intervention: Standard therapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 31760132

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 31173551

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study: 25799085

Group type: EXPERIMENTAL
Intervention: Perflubron-induced lung growth (PILG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 16
Study: 21899792

Group type: EXPERIMENTAL
Intervention: Exposure plus reward (E + R)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Exposure only (EO)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control
Number of subjects: 185
Study: 21620416

Group type: EXPERIMENTAL
Intervention: Vitamin D3 as add-on therapy to subcutaneous interferon β-1a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo as add-on therapy to subcutaneous interferon β-1a
Number of subjects: 0
Study: 18980263

Group type: EXPERIMENTAL
Intervention: Caffeine (1.75 mg/kg) three times daily for four consecutive weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17164069

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (n=61)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Chlorhexidine/xylitol/sorbitol chewing gum (n=55)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Sodium fluoride/xylitol/sorbitol chewing gum (n=57)
Number of subjects: 173
Study: 14583369

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 to 10 mg once daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 to 25 mg twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 90
Study: 11080722

Group type: EXPERIMENTAL
Intervention: Open food challenge followed by double-blind placebo-controlled food challenges (DBPCFCs)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Skin prick test
Number of subjects: 53

Group type: COMPARATOR
Intervention: Specific IgE measurement
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: DBPCFC
Number of subjects: 53
Study: 8664034

Group type: EXPERIMENTAL
Intervention: Regimen B (daily oral treatment with 30 mg of TAM and 600 mg of FT)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Regimen A (daily oral treatment with 30 mg of TAM)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Regimen C (daily oral treatment with 30 mg of TAM and 3 g of PSK)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Regimen D (daily oral treatment with 600 mg of FT)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Regimen E (daily oral treatment with 3 g of PSK)
Number of subjects: 525
Study: 2071654

Group type: EXPERIMENTAL
Intervention: Unilateral frame with axial micromovement
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unilateral frame in fixed mode
Number of subjects: 80
Study: 6847424

Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31345092

Group type: EXPERIMENTAL
Intervention: USM-guided group
Number of subjects: 136

Group type: COMPARATOR
Intervention: CFM-guided group
Number of subjects: 136
Study: 27555486

Group type: EXPERIMENTAL
Intervention: Interlaminar epidural steroid administration (Group S, n=48) with 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Interlaminar epidural local anesthetic administration (Group L, n=50) with 10 mL 0.25% bupivacaine.
Number of subjects: 98
Study: 26602290

Group type: EXPERIMENTAL
Intervention: Lactoferrin‐fortified formula milk group (FG, containing lactoferrin 38 mg/100 g milk)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Breastfed group (BG)
Number of subjects: 260

Group type: COMPARATOR
Intervention: No lactoferrin‐fortified milk (control group, CG)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Lactoferrin‐fortified formula milk group (FG)
Number of subjects: 260
Study: 24433430

Group type: EXPERIMENTAL
Intervention: Triple therapy (methotrexate/ciclosporin/prednisolone)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Monotherapy (methotrexate)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 431
Study: 23109642

Group type: EXPERIMENTAL
Intervention: Combined procedure (trapezius transfer + teres major transfer)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Single procedure (teres major transfer in isolation)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Group 2a (deltoid power < M3)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Group 2b (deltoid power ≥ M3)
Number of subjects: 35
Study: 19056555

Group type: COMPARATOR
Intervention: Control bar containing 0.3 g beta-glucan from 6.8 g oats
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bar with an additional 0.9 g beta-glucan from 8.0 g barley
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bar with 8 g FOS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bar with 0.9 g beta-glucan + 8 g FOS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bar with 0.9 g beta-glucan
Number of subjects: 21
Study: 18158075

Group type: EXPERIMENTAL
Intervention: Exenatide 10 µg BID
Number of subjects: 138

Group type: COMPARATOR
Intervention: Insulin glargine QD (titrated targeting FSG < or =5.6 mmol/L)
Number of subjects: 138
Study: 15079179

Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg/kg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (oral and nebulized)
Number of subjects: 49
Study: 11586485

Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg twice daily for 4 months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: simvastatin 10 mg daily for 4 months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: gemfibrozil and simvastatin (both treatments)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: gemfibrozil treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: simvastatin treatment
Number of subjects: 23
Study: 9884813

Group type: EXPERIMENTAL
Intervention: dyed aqueous nasal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: vigorous inhalation while spraying
Number of subjects: 0
Study: 9223113

Group type: EXPERIMENTAL
Intervention: Recombinant IL-2 stimulation (7 day culture)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokine (IL-2 and interferon alpha and gamma) induced antitumor activity
Number of subjects: 0
Study: 2667903

Group type: EXPERIMENTAL
Intervention: Doxycycline plus streptomycin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Doxycycline plus rifampin
Number of subjects: 111
Study: 913863

Group type: EXPERIMENTAL
Intervention: 40 mg oxprenolol every six hours during marathon bowling
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Single dose of 40 mg oxprenolol 60 minutes prior to shooting matches
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31359526

Group type: EXPERIMENTAL
Intervention: Compulsory community treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Critique of trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research strategy
Number of subjects: 0
Study: 31201890

Group type: EXPERIMENTAL
Intervention: Nasal microbiota dominated by Moraxella species
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Nasal microbiota dominated by Staphylococcus or Corynebacterium species
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Nasal microbiota dominated by Streptococcus species
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Moraxella catarrhalis (in vitro)
Number of subjects: 413
Study: 27612487

Group type: EXPERIMENTAL
Intervention: Individual feedback group (n = 36) that received a daily alarm and a weekly medication adherence feedback report
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Partner feedback group (n = 54) that received an alarm and a weekly feedback report shared with a friend, family member, or peer
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (n = 36) that received a pill‐monitoring device with no alarms or feedback
Number of subjects: 126
Study: 26083701

Group type: EXPERIMENTAL
Intervention: Alpine skiing for 12 weeks (Intervention Group - IG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 23
Study: 23135345

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/day
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/day with vitamin D
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 21596994

Group type: COMPARATOR
Intervention: Pregabalin 200 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Pregabalin 75 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 62
Study: 20064186

Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 135

Group type: COMPARATOR
Intervention: Echinacea
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 16456197

Group type: EXPERIMENTAL
Intervention: Power training at 20% (LOW)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Power training at 50% (MED)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Power training at 80% (HIGH)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Low intensity power training (20%)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (nontraining)
Number of subjects: 112
Study: 15367065

Group type: EXPERIMENTAL
Intervention: Long-interval traumatic writing condition
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Short-interval traumatic writing condition
Number of subjects: 546

Group type: COMPARATOR
Intervention: Nonemotional writing control condition
Number of subjects: 546
Study: 11308064

Group type: EXPERIMENTAL
Intervention: Coping intervention
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Coping intervention (for those attending at least half of the sessions)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Mutual support control group
Number of subjects: 168

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 168
Study: 9291170

Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg daily for 2 days administered every 4 weeks for 24 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 25